Drugs / Englumafusp alfa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04077723 | Aug 2019 → Mar 2027 expected | non-Hodgkin lymphoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-05 | Hoffmann-La Roche | Results Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 roche.com ↗
Englumafusp alfa (CD19-4-1BBL) combined with glofitamab is safe and efficacious in patients with r/r B-NHL: extended follow up analysis of the dose-escalation part of Phase 1 trial BP41072 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-05 | Hoffmann-La Roche | Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 roche.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Englumafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04077723 ↗ |
| Known as | Ensomafusp alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095378 ↗ |
| Known as | RG-6076 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095378 ↗ |
| Known as | RO-7227166 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095378 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5095378 ↗ |
| Target | CD19 | “A CD19 Targeted 4-1BB Ligand” NCT04077723 ↗ |